middle.news
Dimerix’s DMX-200 Clears Seventh Safety Review in Pivotal FSGS Trial
9:15am on Wednesday 19th of November, 2025 AEDT
•
Biotechnology
Read Story
Dimerix’s DMX-200 Clears Seventh Safety Review in Pivotal FSGS Trial
9:15am on Wednesday 19th of November, 2025 AEDT
Key Points
Seventh scheduled IDMC review completed successfully
No safety concerns raised; trial continues unchanged
271 patients randomized and dosed as of November 2025
DMX-200 shows emerging strong safety profile
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE